SEARCH

SEARCH BY CITATION

References

  • Akpek, G., Zahurak, M.L., Piantadosi, S., Margolis, J., Doherty, J., Davidson, R. & Vogelsang, G.B. (2001a) Development of a prognostic model for grading chronic graft-versus-host disease. Blood, 97, 12191226.
  • Akpek, G., Lee, S.M., Anders, V. & Vogelsang, G.B. (2001b) A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 7, 495502.
  • Allison, A.C. & Eugui, E.M. (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation, 80, S181S190.
  • Apisarnthanarax, N., Donato, M., Körbling, M., Couriel, D., Gajewski, J., Giralt, S., Khouri, I., Hosing, C., Champli, N.R., Duvic, M. & Anderlini, P. (2003) Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplantation, 31, 459465.
  • Arora, M., Wagner, J.E., Davies, S.M., Blazar, B.R., Defor, T., Enright, H., Miller, W.J. & Weisdorf, D.F. (2001) Randomized clinical trial of thalidomide, ciclosporin, and prednisone versus ciclosporin and prednisone as initial therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 7, 265273.
  • Arora, M., Klein, J.P., Weisdorf, D.J., Hassebroek, A., Flowers, M.E., Cutler, C.S., Urbano-Ispizua, A., Antin, J.H., Bolwell, B.J., Boyiadzis, M., Cahn, J.Y., Cairo, M.S., Isola, L., Jacobsohn, D.A., Jagasia, M., Klumpp, T.R., Lee, S.J., Petersdorf, E.W., Santarone, S., Gale, R.P., Schouten, H.C., Spellman, S., Wingard, J.R., Horowitz, M.M. & Pavletic, S.Z. (2011) Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 117, 67146720.
  • Baird, K. & Pavletic, S.Z. (2006) Chronic graft versus host disease. Current Opinion in Hematology, 6, 426435.
  • Baudard, M., Vincent, A., Moreau, P., Kergueris, M.F., Harousseau, J.L. & Milpied, N. (2002) Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplantation, 5, 287295.
  • Blanke, C. (2010) Current management of GISTs. Clinical Advances in Hematology and Oncology, 5, 334.
  • von Bonin, M., Oelschlägel, U., Radke, J., Stewart, M., Ehninger, G., Bornhauser, M. & Platzbecker, U. (2008) Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation, 86, 875879.
  • Bonner, J.C. (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine & Growth Factor Reviews, 4, 255273.
  • Browne, P.V., Weisdorf, D.J., DeFor, T., Miller, W.J., Davies, S.M., Filipovich, A., McGlave, P.B., Ramsay, N.K., Wagner, J. & Enright, H. (2000) Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplantation, 26, 865869.
  • Bullorsky, E.O., Shanley, C.M., Stemmelin, G.R., Musso, A., Rabinovich, O., Ceresetto, J. & Quiroga, L. (1993) Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplantation, 11, 7576.
  • Busca, A., Locatelli, F., Marmont, F., Audisio, E. & Falda, M. (2003) Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica, 88, 837839.
  • Busca, A., Locatelli, F., Lovisone, E., Ottobrelli, A., Boggio, D., Novero, D. & Falda, M. (2005) Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biology of Blood and Marrow Transplantation, 11, 734736.
  • Busca, A., Locatelli, F., Marmont, F., Ceretto, C. & Falda, M. (2007) Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 82, 4552.
  • Carella, A.M., Beltrami, G., Scalzulli, P.R., Carella A.M. Jr & Corsetti, M.T. (2004) Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplantation, 33, 131132.
  • Carnevale-Schianca, F., Martin, P., Sullivan, K., Flowers, M., Gooley, T., Anasetti, C., Deeg, J., Furlong, T., McSweeney, P., Storb, R. & Nash, R.A. (2000) Changing from ciclosporin to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 6, 613620.
  • Chiang, K.Y., Abhyankar, S., Bridges, K., Godder, K. & Henslee-Downey, J.P. (2002) Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation, 73, 665667.
  • Child, F.J., Ratnavel, R., Watkins, P., Samson, D., Apperley, J., Ball, J., Taylor, P. & Russell-Jones, R. (1999) Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplantation, 23, 881887.
  • Couriel, D.R., Saliba, R., Escalón, M.P., Hsu, Y., Ghosh, S., Ippoliti, C., Hicks, K., Donato, M., Giralt, S., Khouri, I.F., Hosing, C., de Lima, M.J., Andersson, B., Neumann, J. & Champlin, R. (2005) Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. British Journal of Haematology, 130, 409417.
  • Couriel, D., Carpenter, P.A., Cutler, C., Bolaños-Meade, J., Treister, N.S., Gea-Banacloche, J., Shaughnessy, P., Hymes, S., Kim, S., Wayne, A.S., Chien, J.W., Neumann, J., Mitchell, S., Syrjala, K., Moravec, C.K., Abramovitz, L., Liebermann, J., Berger, A., Gerber, L., Schubert, M., Filipovich, A.H., Weisdorf, D., Schubert, M.M., Shulman, H., Schultz, K., Mittelman, B., Pavletic, S., Vogelsang, G.B., Martin, P.J., Lee, S.J. & Flowers, M.E. (2006a) Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biology of Blood and Marrow Transplantation, 12, 375396.
  • Couriel, D.R., Hosing, C., Saliba, R., Shpall, E.J., Anderlini, P., Rhodes, B., Smith, V., Khouri, I., Giralt, S., de Lima, M., Hsu, Y., Ghosh, S., Neumann, J., Andersson, B., Qazilbash, M., Hymes, S., Kim, S., Champlin, R. & Donato, M. (2006b) Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 107, 30743080.
  • Curtis, R.E., Metayer, C., Rizzo, J.D., Socié, G., Sobocinski, K.A., Flowers, M.E., Travis, W.D., Travis, L.B., Horowitz, M.M. & Deeg, H.J. (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood, 105, 38023811.
  • Cutler, C., Miklos, D., Kim, H.T., Treister, N., Woo, S.B., Bienfang, D., Klickstein, L.B., Levin, J., Miller, K., Reynolds, C., Macdonell, R., Pasek, M., Lee, S.J., Ho, V., Soiffer, R., Antin, J.H., Ritz, J. & Alyea, E. (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 108, 756762.
  • Deeg, H. (2007) How I treat refractory acute GVHD. Blood, 109, 41194126.
  • Devergie, A., (2008) Graft versus host disease, chapter 11. In: ESH-EBMT Handbook (eds J. Apperley, E. Carreras, E. Gluckman, A. Gratwohl & T. Masszi), pp. 218236. Forum Service Editore, Genoa, Italy.
  • Dignan, F.L., Greenblatt, D., Cox, M., Cavenagh, J., Oakervee, H., Apperley, J.F., Fielding, A.K., Pagliuca, A., Mufti, G., Raj, K., Marks, D.I., Amrolia, P., Peniket, A., Medd, P., Potter, M.N., Shaw, B.E. & Scarisbrick, J.J. (2011) Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplantation, 19. doi: 10.1038/bmt.2011.186 [Epub ahead of print].
  • Dignan, F.L., Clark, A., Amrolia, P., Cornish, J., Jackson, G., Mahendra, P., Scarisbrick, J.J., Taylor, P.C., Hadzic, N., Shaw, B.E., Potter, M.N. & on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation (2012a) Diagnosis and management of acute graft-versus-host disease. British Journal of Haematology, 158, 3045.
  • Dignan, F.L., Scarisbrick, J.J., Cornish, J., Clark, A., Amrolia, P., Jackson, G., Mahendra, P., Taylor, P.C., Shah, P., Lightman, S., Fortune, F., Kibbler, C., Andreyev, J., Albanese, A., Hadzic, N., Potter, M.N., Shaw, B.E. & on behalf of the Haemato-Oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation (2012b) Organ-specific management and supportive care in graft-versus-host disease. British Journal of Haematology, 158, 6278
  • Dumler, F., Levin, N.W., Szego, G., Vulpetti, A.T. & Preuss, L.E. (1982) Long-term alternate day steroid therapy in renal transplantation. A controlled study. Transplantation, 34, 7882.
  • Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G. & Flowers, M.E. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11, 945956.
  • Flowers, M.E., Apperley, J.F., van Besien, K., Elmaagacli, A., Grigg, A., Reddy, V., Bacigalupo, A., Kolb, H.J., Bouzas, L., Michallet, M., Prince, H.M., Knobler, R., Parenti, D., Gallo, J. & Greinix, H.T. (2008) A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood, 112, 26672674.
  • Foss, F.M., DiVenuti, G.M., Chin, K., Sprague, K., Grodman, H., Klein, A., Chan, G., Stiffler, K. & Miller, K.B. (2005) Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation, 35, 11871193.
  • Furlong, T, Martin, P, Flowers, ME, Carnevale-Schianca, F, Yatscoff, R, Chauncey, T, Appelbaum, FR, Deeg, HJ, Doney, K, Witherspoon, R, Storer, B, Sullivan, KM, Storb, R & Nash, RA. (2009) Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplantation, 44, 73948.
  • Ghofrani, H.A., Seeger, W. & Grimminger, F. (2005) Imatinib for the treatment of pulmonary arterial hypertension. New England Journal of Medicine, 353, 14121413.
  • Ghoreschi, K., Thomas, P., Penovici, M., Ullmann, J., Sander, C.A., Ledderose, G., Plewig, G., Kolb, H.J. & Röcken, M. (2008) PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. European Journal of Dermatology, 18, 667670.
  • Giaccone, L., Martin, P., Carpenter, P., Moravec, C., Hooper, H., Funke, V.A., Storb, R. & Flowers, M.E. (2005) Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplantation, 36, 337341.
  • Gilman, A.L., Chan, K.W., Mogul, A., Morris, C., Goldman, F.D., Boyer, M., Cirenza, E., Mazumder, A., Gehan, E., Cahill, R., Frankel, S. & Schultz, K. (2000) Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 6, 327334.
  • Gilman, A.L., Schultz, K.R., Goldman, F.D., Sale, G.E., Krailo, M.D., Chen, Z., Langholz, B., Jacobsohn, D.A., Chan, K.W., Ryan, R.E., Kellick, M., Neudorf, S.M., Godder, K., Sandler, E.S., Sahdev, I., Grupp, S.A., Sanders, J.E. & Wall, D.A. (2012) Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group Study. Biology of Blood and Marrow Transplantation, 18, 8491.
  • Giralt, S. (2006) The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Seminars in Oncology, 33, S36S43.
  • Giralt, S.A., Arora, M., Goldman, J.M., Lee, S.J., Maziarz, R.T., McCarthy, P.L., Sobocinski, K.A. & Horowitz, M.M. (2007) Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British Journal of Haematology, 137, 461467.
  • Greinix, H.T. (2008) Graft-Versus-Host Disease. UNI-MED Verlag AG, Bremen, Germany, 7273.
  • Greinix, H.T., Volc-Platzer, B., Rabitsch, W., Gmeinhart, B., Guevara-Pineda, C., Kalhs, P., Krutmann, J., Hönigsmann, H., Ciovica, M. & Knobler, R.M. (1998) Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host-disease. Blood, 92, 30983104.
  • Greinix, H.T., Socié, G., Bacigalupo, A., Holler, E., Edinger, M.G., Apperley, J.F., Schwarz, T., Ullrich, S.E., Albert, M.L., Knobler, R.M., Peritt, D. & Ferrara, J.L. (2006) Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplantation, 38, 265273.
  • Greinix, H.T., Loddenkemper, C., Pavletic, S.Z., Holler, E., Socié, G., Lawitschka, A., Halter, J. & Wolff, D. (2011) Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice. Biology of Blood and Marrow Transplantation, 17, 167175.
  • Hiwarkar, P., Shaw, B.E., Tredger, J.M., Brown, N.W., Kulkarni, S., Saso, R., Evans, S., Treleaven, J., Davies, F.E., Ethell, M.E., Morgan, G.J. & Potter, M.N. (2011) Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. Clinical Transplantation, 25, 222227.
  • Huang, X.J., Jiang, Q., Chen, H., Xu, L., Liu, D., Chen, Y., Han, W., Zhang, Y., Liu, K. & Lu, D. (2005) Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 36, 343348.
  • Inagaki, J., Nagatoshi, Y., Hatano, M., Isomura, N., Sakiyama, M. & Okamura, J. (2008) Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplantation, 41, 571577.
  • Jabs, K., Sullivan, E.K., Avner, E.D. & Harmon, W.E. (1996) Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation, 61, 3136.
  • Jacobsohn, D.A., Chen, A.R., Zahurak, M., Piantadosi, S., Anders, V., Bolaños-Meade, J., Higman, M., Margolis, J., Kaup, M. & Vogelsang, G.B. (2007) Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. Journal of Clinical Oncology, 25, 42554261.
  • Jacobsohn, D.A., Gilman, A.L., Rademaker, A., Browning, B., Grimley, M., Lehmann, L., Nemecek, E.R., Thormann, K., Schultz, K.R. & Vogelsang, G.B. (2009) Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood, 114, 43544360.
  • Jagasia, M.H., Savani, B.N., Stricklin, G., Engelhardt, B., Kassim, A., Dixon, S., Chen, H., Chinratanalab, W., Goodman, S., Greer, J.P. & Schuening, F. (2009) Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biology of Blood and Marrow Transplantation, 15, 12881295.
  • Johnston, L.J., Brown, J., Shizuru, J.A., Stockerl-Goldstein, K.E., Stuart, M.J., Blume, K.G., Negrin, R.S. & Chao, N.J. (2005) Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 4755.
  • Joint Formulary Committee (2011) British National Formulary, No 62 (September 2011). Pharmaceutical Press, London.
  • Jurado, M., Vallejo, C., Pérez-Simón, J.A., Brunet, S., Ferra, C., Balsalobre, P., Pérez-Oteyza, J., Espigado, I., Romero, A., Caballero, D., Sierra, J., Ribera, J.M. & Díez, J.L. (2007) Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 13, 701706.
  • Kanamaru, A., Takemoto, Y., Kakishita, E., Dohy, H., Kodera, Y., Moriyama, Y., Shibata, A., Kasai, M., Katoh, S., Saitoh, H., Matsuda, T., Hattori, M., Okamoto, S., Asano, S., Horiuchi, A., Harada, M., Hiraoka, A. & Masaoka, T.for.the.Japanese.F.K506.B.M.T.Study.Group. (1995) FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with ciclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplantation, 15, 885889.
  • Keifer, J.A., Guttridge, D.C., Ashburner, B.P. & Baldwin, Jr, A.S. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. The Journal of Biological Chemistry, 276, 2238222387.
  • Kharfan-Dabaja, M.A., Mhaskar, A.R., Djulbegovic, B., Cutler, C., Mohty, M. & Kumar, A. (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biology of Blood and Marrow Transplantation, 15, 10051013.
  • Kim, S.J., Lee, J.W., Jung, C.W., Min, C.K., Cho, B., Shin, H.J., Chung, J.S., Kim, H., Lee, W.S., Joo, Y.D., Yang, D.H., Kook, H., Kang, H.J., Ahn, H.S., Yoon, S.S., Sohn, S.K., Min, Y.H., Min, W.S., Park, H.S. & Won, J.H. (2010) Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica, 95, 19351942.
  • Klink, A., Schilling, K., Rapp, K., Höffken, K. & Sayer, H.G. (2008) High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), 112, 2210.
  • Koc, S., Leisenring, W., Flowers, M.E., Anasetti, C., Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Appelbaum, F.R., Storb, R. & Martin, P.J. (2000) Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 96, 39953996.
  • Koc, S., Leisenring, W., Flowers, M.E., Anasetti, C., Deeg, H.J., Nash, R.A., Sanders, J.E., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Martin, P.J. (2002) Therapy for chronic graft-versus-host disease: a randomized trial comparing ciclosporine plus prednisone versus prednisone alone. Blood, 100, 4851.
  • Krejci, M., Doubek, M., Buchler, T., Brychtova, Y., Vorlicek, J. & Mayer, J. (2005) Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology, 84, 681685.
  • Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Saso, R., Horton, C., Atra, A., Ortin, M., Rudin, C., Goyal, S., Sankpal, S., Meller, S., Pinkerton, C.R., Mehta, J. & Singhal, S. (2003) Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplantation, 32, 165170.
  • Kuzmina, Z. & Greinix, H.T. (2009) Proportions of immature CD19CD21 B lymphocytes may predict the response to extracorporeal photopheresis in patients with chronic graft versus host disease. Blood, 114, 744745.
  • de Lavallade, H., Mohty, M., Faucher, C., Fürst, S., El-Cheikh, J. & Blaise, D. (2006) Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica, 91, 14381440.
  • Lee, S.J. & Flowers, M.E. (2008) Recognizing and managing chronic graft-versus-host disease. Hematology, American Society of Hematology Education Program, 13, 441.
  • Lee, S.J., Wegner, S.A., McGarigle, C.J., Bierer, B.E. & Antin, J.H. (1997) Treatment of chronic graft-versus-host disease with clofazimine. Blood, 89, 22982302.
  • Lee, S.J., Klein, J.P., Barrett, A.J., Ringden, O., Antin, J.H., Cahn, J.Y., Carabasi, M.H., Gale, R.P., Giralt, S., Hale, G.A., Ilhan, O., McCarthy, P.L., Socie, G., Verdonck, L.F., Weisdorf, D.J. & Horowitz, M.M. (2002) Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 100, 406414.
  • Lepper, E.R., Smith, N.F., Cox, M.C., Scripture, C.D. & Figg, W.D. (2006) Thalidomide metabolism and hydrolysis: mechanisms and implications. Current Drug Metabolism, 7, 677685.
  • Lopez, F., Parker, P., Nademanee, A., Rodriguez, R., Al-Kadhimi, Z., Bhatia, R., Cohen, S., Falk, P., Fung, H., Kirschbaum, M., Krishnan, A., Kogut, N., Molina, A., Nakamura, R., O'Donnell, M., Popplewell, L., Pullarkat, V., Rosenthal, J., Sahebi, F., Smith, E., Snyder, D., Somlo, G., Spielberger, R., Stein, A., Sweetman, R., Zain, J. & Forman, S. (2005) Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 307313.
  • Magro, L., Mohty, M., Catteau, B., Coiteux, V., Chevallier, P., Terriou, L., Jouet, J.P. & Yakoub-Agha, I. (2009) Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood, 114, 719722.
  • Majhail, N.S., Schiffer, C.A. & Weisdorf, D.J. (2006) Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 12, 789791.
  • Marcellus, D.C., Altomonte, V.L., Farmer, E.R., Horn, T.D., Freemer, C.S., Grant, J. & Vogelsang, G.B. (1999) Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood, 93, 6670.
  • Margolis, J. & Vogelsang, G. (2000) An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Seminars in Oncology, 27, 7277.
  • Martin, P.J., Weisdorf, D., Przepiorka, D., Hirschfeld, S., Farrell, A., Rizzo, J.D., Foley, R., Socie, G., Carter, S., Couriel, D., Schultz, K.R., Flowers, M.E., Filipovich, A.H., Saliba, R., Vogelsang, G.B., Pavletic, S.Z. & Lee, S.J. (2006) Design of Clinical Trials Working Group.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biology of Blood and Marrow Transplantation, 12, 491505.
  • Martin, P.J., Storer, B.E., Rowley, S.D., Flowers, M.E., Lee, S.J., Carpenter, P.A., Wingard, J.R., Shaughnessy, P.J., DeVetten, M.P., Jagasia, M., Fay, J.W., van Besien, K., Gupta, V., Kitko, C., Johnston, L.J., Maziarz, R.T., Arora, M., Jacobson, P.A. & Weisdorf, D. (2009) Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 113, 50745082.
  • Mayer, J., Krejcí, M., Doubek, M., Pospísil, Z., Brychtová, Y., Tomíska, M. & Rácil, Z. (2005) Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplantation, 35, 699705.
  • Messina, C., Locatelli, F., Lanino, E., Uderzo, C., Zacchello, G., Cesaro, S., Pillon, M., Perotti, C., Del Fante, C., Faraci, M., Rivabella, L., Calore, E., De Stefano, P., Zecca, M., Giorgiani, G., Brugiolo, A., Balduzzi, A., Dini, G., Zanesco, L. & Dall'Amico, R. (2003) Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. British Journal of Haematology, 122, 118127.
  • Mohty, M., Marchetti, N., El-Cheikh, J., Faucher, C., Fürst, S. & Blaise, D. (2008) Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplantation, 41, 909911.
  • Mookerjee, B., Altomonte, V. & Vogelsang, G. (1999) Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation, 24, 517520.
  • Moreira, V., De Medeiros, B.C., Bonfim, C.M., Pasquini, R. & De Medeiros, C.R. (1998) Methemoglobinemia secondary to clofazimine treatment for chronic graft-versus-host disease. Blood, 92, 48724873.
  • Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., Gabrielli, A. & Bacigalupo, A. (2009) Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 114, 709718.
  • Onishi, C., Ohashi, K., Sawada, T., Nakano, M., Kobayashi, T., Yamashita, T., Akiyama, H. & Sakamaki, H. (2010) A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology, 91, 464470.
  • Parfitt, J.R., Jayakumar, S. & Driman, D.K. (2008) Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. American Journal of Surgical Pathology, 32, 13671372.
  • Park, S.H., Choi, S.M., Lee, D.G., Choi, J.H., Yoo, J.H., Kim, S.H., Kim, H.J., Cho, S.G., Eom, K.S., Lee, J.W., Min, W.S., Shin, W.S. & Kim, C.C. (2009) Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transplant Infectious Disease, 11, 413423.
  • Parker, P.M., Chao, N., Nademanee, A., O'Donnell, M.R., Schmidt, G.M., Snyder, D.S., Stein, A.S., Smith, E.P., Molina, A., Stepan, D.E., Kashyap, A., Planas, I., Spielberger, R., Somlo, G., Margolin, K., Zwingenberger, K., Wilsman, K., Negrin, R.S., Long, G.D., Niland, J.C., Blume, K.G. & Forman, S.J. (1995) Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood, 86, 36043609.
  • Pavletic, S.Z., Martin, P., Lee, S.J., Mitchell, S., Jacobsohn, D., Cowen, E.W., Turner, M.L., Akpek, G., Gilman, A., McDonald, G., Schubert, M., Berger, A., Bross, P., Chien, J.W., Couriel, D., Dunn, J.P., Fall-Dickson, J., Farrell, A., Flowers, M.E., Greinix, H., Hirschfeld, S., Gerber, L., Kim, S., Knobler, R., Lachenbruch, P.A., Miller, F.W., Mittleman, B., Papadopoulos, E., Parsons, S.K., Przepiorka, D., Robinson, M., Ward, M., Reeve, B., Rider, L.G., Shulman, H., Schultz, K.R., Weisdorf, D., Vogelsang, G.B. & Response Criteria Working Group (2006) Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biology of Blood and Marrow Transplantation, 12, 252266.
  • Peleg, A.Y., Husain, S., Kwak, E.J., Silveira, F.P., Ndirangu, M., Tran, J., Shutt, K.A., Shapiro, R., Thai, N., Abu-Elmagd, K., McCurry, K.R., Marcos, A. & Paterson, D.L. (2007) Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clinical Infectious Disease, 44, 204212.
  • Perseghin, P., Galimberti, S., Balduzzi, A., Bonanomi, S., Baldini, V., Rovelli, A., Dassi, M., Rambaldi, A., Castagna, L., Corti, P., Pogliani, E.M. & Uderzo, C. (2007) Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? Therapeutic Apheresis and Dialysis Journal, 11, 8593.
  • Pidala, J., Kim, J., Roman-Diaz, J., Shapiro, J., Nishihori, T., Bookout, R., Anasetti, C. & Kharfan-Dabaja, M.A. (2010) Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Annals of Transplantation, 15, 2129.
  • Pusic, I., Pavletic, S.Z., Kessinger, A., Tarantolo, S.R. & Bishop, M.R. (2002) Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplantation, 29, 709710.
  • Ratanatharathorn, V., Carson, E., Reynolds, C., Ayash, L.J., Levine, J., Yanik, G., Silver, S.M., Ferrara, J.L. & Uberti, J.P. (2000) Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Annals of Internal Medicine, 133, 275279.
  • Robin, M., Guardiola, P., Girinsky, T., Hernandez, G., Espérou, H., Ribaud, P., Rocha, V., Garnier, F., Socié, G., Gluckman, E. & Devergie, A. (2005) Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation, 80, 634642.
  • Rodriguez, V., Anderson, P.M., Trotz, B.A., Arndt, C.A., Allen, J.A. & Khan, S.P. (2007) Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatric Blood Cancer, 49, 212215.
  • Rovelli, A., Arrigo, C., Nesi, F., Balduzzi, A., Nicolini, B., Locasciulli, A., Vassallo, E., Miniero, R. & Uderzo, C. (1998) The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplantation, 21, 577581.
  • Ruiz-Argüelles, G.J., Gil-Beristain, J., Magaña, M. & Ruiz-Delgado, G.J. (2008) Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 14, 79.
  • Rzepecki, P., Barzal, J., Sarosiek, T., Oborska, S. & Szczylik, C. (2007) How can we help patients with refractory chronic graft versus host disease- single centre experience. Neoplasma, 54, 431436.
  • Scarisbrick, J. (2009) Extracorporeal photopheresis: what is it and when should it be used? Clinical Experimental Dermatology, 34, 757760.
  • Scarisbrick, J.J., Taylor, P., Holtick, U., Makar, Y., Douglas, K., Berlin, G., Juvonen, E. & Marshall, S.Photopheresis.Expert.Group. (2008) U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. British Journal of Dermatology, 158, 659678.
  • Schultz, K.R., Miklos, D.B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., Holler, E., Ferrara, J., Shulman, H., Lee, S.J., Martin, P., Filipovich, A.H., Flowers, M.E., Weisdorf, D., Couriel, D., Lachenbruch, P.A., Mittleman, B., Vogelsang, G.B. & Pavletic, S.Z. (2006) Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 12, 126137.
  • Seaton, E.D., Szydlo, R.M., Kanfer, E., Apperley, J.F. & Russell-Jones, R. (2003) Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood, 102, 12171223.
  • Shapira, M.Y., Abdul-Hai, A., Resnick, I.B., Bitan, M., Tsirigotis, P., Aker, M., Gesundheit, B., Slavin, S. & Or, R. (2009) Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplantation, 43, 339343.
  • Shulman, H.M., Sullivan, K.M., Weiden, P.L., McDonald, G.B., Striker, G.E., Sale, G.E., Hackman, R., Tsoi, M.S., Storb, R. & Thomas, E.D. (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. American Journal of Medicine, 69, 204217.
  • Shulman, H.M., Kleiner, D., Lee, S.J., Morton, T., Pavletic, S.Z., Farmer, E., Moresi, J.M., Greenson, J., Janin, A., Martin, P.J., McDonald, G., Flowers, M.E., Turner, M., Atkinson, J., Lefkowitch, J., Washington, M.K., Prieto, V.G., Kim, S.K., Argenyi, Z., Diwan, A.H., Rashid, A., Hiatt, K., Couriel, D., Schultz, K., Hymes, S. & Vogelsang, G.B. (2006) Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 12, 3147.
  • Sleight, B.S., Chan, K.W., Braun, T.M., Serrano, A. & Gilman, A.L. (2007) Infliximab for GVHD therapy in children. Bone Marrow Transplantation, 40, 473480.
  • Stadler, M., Ahlborn, R., Kamal, H., Diedrich, H., Buchholz, S., Eder, M. & Ganser, A. (2009) Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood, 114, 37183719.
  • Sullivan, K.M., Witherspoon, R.P., Storb, R., Deeg, H.J., Dahlberg, S., Sanders, J.E., Appelbaum, F.R., Doney, K.C., Weiden, P., Anasetti, C., Loughran, T.P., Hill, R., Shields, A., Yee, G., Shulman, H., Nims, J., Strom, S. & Thomas, E.D. (1988a) Alternating-day ciclosporin and prednisone for treatment of high-risk chronic graft-v-host disease. Blood, 72, 555561.
  • Sullivan, K.M., Witherspoon, R.P., Storb, R., Weiden, P., Flournoy, N., Dahlberg, S., Deeg, H.J., Sanders, J.E., Doney, K.C., Appelbaum, F.R., McGuffin, R., McDonald, G.B., Meyers, J., Schubert, M.M., Gauvreau, J., Shulman, H.M., Sale, G.E., Anasetti, C., Loughran, T.P., Strom, S., Nims, J. & Thomas, E.D. (1988b) Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood, 72, 546554.
  • Takami, A., Mochizuki, K., Okumura, H., Ito, S., Suga, Y., Yamazaki, H., Yamazaki, M., Kondo, Y., Asakura, H. & Nakao, S. (2006) Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology, 83, 8085.
  • Teachey, D.T., Bickert, B. & Bunin, N. (2006) Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplantation, 37, 9599.
  • Toor, A.A., Stiff, P.J., Nickoloff, B.J., Rodriguez, T., Klein, J.L. & Gordon, K.B. (2007) Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. Journal of Dermatological Treatment, 18, 1318.
  • Tzakis, A.G., Abu-Elmagd, K., Fung, J.J., Bloom, E.J., Nour, B., Greif, F. & Starzl, T.E. (1991) FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proceedings, 23, 32253227.
  • Vogelsang, G.B., Farmer, E.R., Hess, A.D., Altamonte, V., Beschorner, W.E., Jabs, D.A., Corio, R.L., Levin, L.S., Colvin, O.M., Wingard, J.R. & Santos, G.W. (1992) Thalidomide for the treatment of chronic graft-versus-host disease. New England Journal of Medicine, 326, 10551058.
  • Wandroo, F., Auguston, B., Cook, M., Craddock, C. & Mahendra, P. (2004) Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplantation, 34, 285287.
  • Wang, Y., Xu, L.P., Liu, D.H., Chen, H., Chen, Y.H., Han, W., Liu, K.Y. & Huang, X.J. (2009) First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. Biology of Blood and Marrow Transplantation, 15, 505511.
  • Weng, J.Y., Du, X., Geng, S.X., Peng, Y.W., Wang, Z., Lu, Z.S., Wu, S.J., Luo, C.W., Guo, R., Ling, W., Deng, C.X., Liao, P.J. & Xiang, A.P. (2010) Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplantation, 45, 17321740.
  • Whittle, R. & Taylor, P.C. (2011) Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. Blood, 118, 64466449.
  • Whittle, R., Hammerton, F., Denney, H. & Taylor, P.C. (2011) Higher leucoyte dose in ECP therapy is associated with superior outcomes for chronic GVHD. Bone Marrow Transplantation, 46, S98.
  • Willenbacher, W., Basara, N., Blau, I.W., Fauser, A.A. & Kiehl, M.G. (2001) Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology, 112, 820823.
  • Wolff, D., Gerbitz, A., Ayuk, F., Kiani, A., Hildebrandt, G.C., Vogelsang, G.B., Elad, S., Lawitschka, A., Socie, G., Pavletic, S.Z., Holler, E. & Greinix, H. (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biology of Blood and Marrow Transplantation, 16, 16111628.
  • Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G.B., Kobbe, G., Gramatzki, M., Lawitschka, A., Mohty, M., Pavletic, S.Z., Greinix, H. & Holler, E. (2011) Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 17, 117.
  • Zaja, F., Bacigalupo, A., Patriarca, F., Stanzani, M., Van Lint, M.T., Filì, C., Scimè, R., Milone, G., Falda, M., Vener, C., Laszlo, D., Alessandrino, P.E., Narni, F., Sica, S., Olivieri, A., Sperotto, A., Bosi, A., Bonifazi, F., Fanin, R. & GITMO (Gruppo Italiano Trapianto Midollo Osseo) (2007) Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplantation, 40, 273277.